BioMarin Pharma (BMRN) Misses Q1 EPS by 14c

BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.32), $0.14 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $400 million versus the consensus estimate of $389.69 million.

• 2019 Full-Year Financial Guidance unchanged

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• Pony AI (PONY) Reports Revenue Above Estimates
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance